BioSpace News Archive

Drug Development

CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients With Primary Biliary Cholangitis

The objectives of the study are to provide additional long-term safety and efficacy data that will support the seladelpar registration program and to follow patients until registration of seladelpar.

January 8, 2018
·
5 min read
Business

CymaBay Therapeutics Receives $5M Milestone Payment for Arhalofenate From Kowa Pharmaceuticals America

The two companied inked the deal in December 2016.

January 8, 2018
·
4 min read
Biotech Bay

Biotricity Expands its R&D Effort to Capitalize on Artificial Intelligence

Properly executed this could lead to an improvement in detection quality and patient outcomes while driving down costs and potentially providing another product opportunity for Biotricity.

January 8, 2018
·
5 min read
Lone Star Bio

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately.

January 8, 2018
·
2 min read
Cytovation Completes NOK 30m Financing Round to Progress Cypep-H1 Through Phase I/IIa Clinical Study in Cutaneous Warts

Cytovation announces it has raised NOK 10m in a private funding round, completing the second stage of fundraising, having raised NOK 20m in June 2017.

January 8, 2018
·
1 min read
Biotech Bay

Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value

The presentation will outline how Agios’ clinical and research programs have the potential to provide meaningful benefit to a large number of patients.

January 8, 2018
·
10 min read
Drug Development

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase II Clinical Trials for Common Warts

Both trials evaluated the safety and efficacy of A-101 45% as compared to placebo (vehicle).

January 8, 2018
·
7 min read
Deals

Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio

The close of the acquisition solidifies Melinta’s position as the world’s largest pure-play antibiotics company.

January 8, 2018
·
8 min read
Business

AxoGen Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue

Fourth quarter revenue is expected to be at least $16.5 million, up 45% compared to the fourth quarter of 2016 revenue of $11.4 million.

January 8, 2018
·
5 min read
Relevium Update On Shares-For-Services Agreement

he shares are subject to a four month hold period. Pricing was determined using the VWAP on the close of January 5, 2018, when submission to the TSX Venture Exchange approval was filed.

January 8, 2018
·
1 min read